Digest Network Come funziona
Network
/
Società
Ve
Non verificato

Verastem Oncology

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

80 comunicati stampa

Guarda tutti i comunicati
06/08/2026
Mercato del lavoro
Mercato azionario
Web e Social Network
Telefonia e Varie
Industria
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
28/07/2026
Industria
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
23/07/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
22/07/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
02/07/2026
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
23/06/2026
Web e Social Network
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
17/06/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
16/06/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
15/06/2026
Web e Social Network
Telefonia e Varie
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
03/06/2026
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0